コンテンツへスキップ
Merck

Bicalutamide treatment for locally advanced prostate cancer.

Hospital medicine (London, England : 1998) (2000-10-26)
J Anderson
要旨

In men with locally advanced prostate cancer, bicalutamide 150 mg monotherapy provides a similar disease outcome to medical or surgical castration. However, castration is associated with loss of sexual interest and function, decreased energy and an increased risk of osteoporotic fractures. Bicalutamide 150 mg monotherapy has less impact on sexual interest and physical capacity than castration.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ビカルタミド(CDX), ≥98% (HPLC), powder
ビカルタミド(CDX), European Pharmacopoeia (EP) Reference Standard
システム適合性用ビカルタミド, European Pharmacopoeia (EP) Reference Standard